Adlyfe signs AD deal with Wyeth

Adlyfe, a private US company developing novel biomarkers and diagnostics for amyloid diseases, has signed an agreement with Wyeth Pharmaceuticals  to develop biomarker assays designed to measure levels of beta amyloid  in the human brain.

The companies will develop assays for specific beta amyloid targets for  use in facilitating the development of treatments for Alzheimer's  disease. The firm's said the multi-year agreement included an upfront  payment and specific future milestones, but further details were not  disclosed.

Chief executive Alan Rudolph said: "this agreement is a strong statement  on the potential of Adlyfe's Pronucleon technology. This partnership  will enable us to move faster in developing our assay, which could serve  as an important tool in assessing the efficacy of amyloid-targeted  therapies."